Benzgalantamine

Add links
Source: Wikipedia, the free encyclopedia.

Benzgalantamine
Clinical data
Trade namesZunveyl
Other namesALPHA-1062
AHFS/Drugs.comZunveyl
License data
By mouth
Drug classCholinesterase inhibitor
ATC code
  • None
Legal status
Legal status
Identifiers
JSmol)
SMILES
  • COc1ccc2c3c1O[C@H]1C[C@@H](OC(=O)c4ccccc4)C=C[C@@]31CCN(C)C2
  • InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1
  • Key:JKVNJTYHRABHIY-WXVUKLJWSA-N

Benzgalantamine, sold under the brand name Zunveyl, is a medication used for the treatment of mild to moderate dementia of the Alzheimer's type.[1] It is a cholinesterase inhibitor.[1] Benzgalantamine is a prodrug of galantamine.[1]

The most common side effects include

decreased appetite.[1]

Benzgalantamine was approved for medical use in the United States in July 2024.[1][2][3]

Medical uses

Benzgalantamine is

indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.[1][2]

Side effects

The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.[1]

Society and culture

Benzgalantamine was approved for medical use in the United States in July 2024.[1][2]

Names

Benzgalantamine is the international nonproprietary name.[4]

References

  1. ^ a b c d e f g h i "Zunveyl- benzgalantamine tablet, delayed release". DailyMed. 8 August 2024. Retrieved 15 August 2024.
  2. ^ a b c https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/218549Orig1s000ltr.pdf
  3. ^ "Alpha Cognition's Oral Therapy Zunveyl Receives FDA Approval to Treat Alzheimer's Disease" (Press release). Alpha Cognition. 29 July 2024. Archived from the original on 4 August 2024. Retrieved 4 August 2024 – via Business Wire.
  4. hdl:10665/363551
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Benzgalantamine&oldid=1268000339"